Korean J Urol.  2015 Jan;56(1):19-30. 10.4111/kju.2015.56.1.19.

The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population

• Choi SY
• Kim HJ
• Cheong HS
• Myung SC

• KMID: 2070265
• DOI: http://doi.org/10.4111/kju.2015.56.1.19

Abstract

PURPOSE
Steroid 5-alpha reductase type 2 (SRD5A2) modifies testosterone to dihydrotestosterone (DHT) in the prostate. Single-nucleotide polymorphisms (SNPs) of the SRD5A2 gene might affect DHT. We sought to understand the relationship of SRD5A2 SNPs to prostate cancer in the Korean population.
MATERIALS AND METHODS
Twenty-six common SNPs in the SRD5A2 gene were assessed in 272 prostate cancer cases and 173 controls. Single-locus analyses were conducted by using conditional logistic regression. Additionally, we performed a haplotype analysis for the SRD5A2 SNPs tested.
RESULTS
Among the 20 SNPs and 4 haplotypes, there were no statistically significant results in the prostate cancer patients and the controls. In the logistic analysis of SRD5A2 polymorphisms with prostate-specific antigen (PSA) criteria, two SNPs (rs508562, rs11675297) and haplotype 1 displayed significant results (odds ratio [OR], 1.76; p=0.05; OR, 1.88-2.02; p=0.01-0.04; OR, 0.59; p=0.02, respectively). rs508562, rs11675297, rs2208532, and haplotype 1 (OR, 1.49; p=0.05; OR, 2.02; p=0.05; OR, 2.01; p=0.04; OR, 0.56-0.64, p=0.03-0.04, respectively) had significant associations with Gleason score. rs508562, rs11675297, and haplotype 1 (OR, 1.41-2.34; p=0.004-0.05; OR, 1.74-1.82; p=0.03-0.05; OR, 0.42-0.67; p=0.0005-0.03, respectively) were significantly associated with clinical stage.
CONCLUSIONS
We conclude that there was no significant association between SRD5A2 SNPs and the risk of prostate cancer in the Korean population. However, we found that some SNPs and 1 haplotype influenced PSA level, Gleason score, and clinical stage.

Keyword

Genetic polymorphism; Human SRD5A2 protein; Prostatic neoplasms

MeSH Terms

3-Oxo-5-alpha-Steroid 4-Dehydrogenase/*genetics
Aged
Case-Control Studies
Dihydrotestosterone/metabolism
Genetic Predisposition to Disease
Genotype
Haplotypes
Humans
Logistic Models
Male
Membrane Proteins/*genetics
Middle Aged
Neoplasm Grading
Neoplasm Staging
Odds Ratio
Polymorphism, Single Nucleotide
Prostate-Specific Antigen/blood
Prostatic Neoplasms/epidemiology/*genetics
Republic of Korea/epidemiology
Risk Factors
Testosterone/genetics
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
Dihydrotestosterone
Membrane Proteins
Prostate-Specific Antigen
Testosterone

Figure

• 

  Fig. 1 (A) Genetic map of SRD5A2 (5-alpha reductase type II) on chromosome 2q23. Coding exons are marked by black boxes, and 5' and 3' UTRs by white boxes. (B) Haplotypes of SRD5A2. The 'Others' category contains rare haplotypes. (C) Linkage disequilibrium (LD) among SRD5A2 polymorphisms. UTR, untranslated region.

Reference

1. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate. 2006; 66:1285–1291.

2. Chan JM, Holick CN, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control. 2006; 17:199–208.

3. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol. 2004; 92:237–253.

4. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995; 55:3973–3975.

5. Bjelfman C, Soderstrom TG, Brekkan E, Norlen BJ, Egevad L, Unge T, et al. Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. J Clin Endocrinol Metab. 1997; 82:2210–2214.

6. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet. 1999; 354:975–978.

7. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res. 1997; 57:1020–1022.

8. Davis DL, Russell DW. Unusual length polymorphism in human steroid 5 alpha-reductase type 2 gene (SRD5A2). Hum Mol Genet. 1993; 2:820.

9. Song SY, Kim SR, Ahn G, Choi HY. Pathologic characteristics of prostatic adenocarcinomas: a mapping analysis of Korean patients. Prostate Cancer Prostatic Dis. 2003; 6:143–147.

10. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques. 2002; Suppl. 56–58. 60–61.

11. Marsell R, Jonsson KB. The phosphate regulating hormone fibroblast growth factor-23. Acta Physiol (Oxf). 2010; 200:97–106.

12. Jung KW, Park S, Won YJ, Kong HJ, Lee JY, Seo HG, et al. Prediction of cancer incidence and mortality in Korea, 2012. Cancer Res Treat. 2012; 44:25–31.

13. Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association analyses. BMC Genet. 2008; 9:36.

14. Hedrick PW. Gametic disequilibrium measures: proceed with caution. Genetics. 1987; 117:331–341.

15. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68:978–989.

16. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004; 74:765–769.

17. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18:1869–1880.

18. Pearce CL, Van Den Berg DJ, Makridakis N, Reichardt JK, Ross RK, Pike MC, et al. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Hum Mol Genet. 2008; 17:2456–2461.

19. Li Q, Zhu Y, He J, Wang M, Zhu M, Shi T, et al. Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis. Mol Biol Rep. 2013; 40:3597–3608.

20. Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol. 2003; 149:469–477.

21. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R. Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab. 2006; 91:4085–4091.

22. Scariano JK, Treat E, Alba F, Nelson H, Ness SA, Smith AY. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Prostate. 2008; 68:1798–1805.

23. Das K, Lorena PD, Ng LK, Lim D, Shen L, Siow WY, et al. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer. 2010; 17:757–770.

24. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999; 54:523–527.

25. West AF, O'Donnell M, Charlton RG, Neal DE, Leung HY. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer. 2001; 85:576–583.

26. Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17:972–977.

27. Setlur SR, Chen CX, Hossain RR, Ha JS, Van Doren VE, Stenzel B, et al. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19:229–239.

28. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol. 2012; 62:757–764.

29. Onen IH, Ekmekci A, Eroglu M, Polat F, Biri H. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol. 2007; 26:100–107.

30. Kim DK, Kim SJ, Moon HS, Park SY, Kim YT, Choi HY, et al. The role of TURP in the detection of prostate cancer in BPH patients with previously negative prostate biopsy. Korean J Urol. 2010; 51:313–317.